Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis.
The histaminergic network in the brain: basic organization and role in disease.
Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.
The genetics of multiple sclerosis.
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies
Neuromyelitis optica with very late onset.
Role of Platelets in Neurodegenerative Diseases: A Universal Pathophysiology.
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?
Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
Central Nervous System Herpes Simplex and Varicella-Zoster Virus Infections in Natalizumab-Treated Patients.
Submembranous cytoskeletons stabilize nodes of Ranvier.
Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
Solodyn
Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.
Epitope spreading in immune-mediated diseases: implications for immunotherapy.
B cells and antibodies in multiple sclerosis pathogenesis and therapy.
MULTIPLE SCLEROSIS: MOLECULAR MECHANISMS AND THERAPEUTIC OPPORTUNITIES.
Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.
High-dose cyclophosphamide in the treatment of multiple sclerosis.
A practical guide to the treatment of neuromyelitis optica.
[Immunodepressive therapy in neurology].
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.
IL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease.
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.

Pages